Lina Radvilaitė – Biomapas Academy Alumni

At the time, I had already finished my Bioengineering studies, but I was continuing them in the Medical Biology field. As for quite some time Biomapas has been stuck in my mind as a prestigious company in the life sciences industry, I would visit their website or social networks for the latest news from time to time.

This is also how I found out about the Biomapas Academy.

 

Why did you choose to become part of the Biomapas Academy?

Actually, it’s mostly because of one conversation that influenced my perspective towards career paths. I have a relative that has become a career consultant. So, at the end of my Medical Biology studies, I figured, why not have a conversation with her? And it turns out that the key takeaway for me was unexpected: I was not open-minded enough about the real-life application of my master’s degree. Now I can see that it was true, but at the time, it was a surprise. I thought that my degree would solely give me a license to work in clinical laboratories in hospitals, but that was not true.

I got convinced that it was time for me to broaden my horizons and look at all possible perspectives a life sciences background can bring. So, I could not resist applying to the Biomapas Academy when I saw the announcement.

 

What was the Biomapas Academy like?

It was great to see how well organized this educational project was and how much you could learn about the main three areas. The lecturers are real experts in their respective fields and share a lot of information. Furthermore, I was surprised by how eventful the field of drug safety can be – we do not see most of it in our daily lives.

What did you do after the Biomapas Academy?

Once I started going to the Academy, one thing led to another. I received an invitation to try myself out in the Pharmacovigilance department as an intern even before the end of the Academy itself. I didn’t doubt much about the offer as the pharmacovigilance field was the one that got my attention the most during the Academy course. You hear about clinical trials a bit more often than what happens after the products reach the market.

Halfway through my internship, the people management team reached out to me about an open position in the QPPV team. It was in an area that piqued my interest, so I decided to apply. After a few interviews, I got the great news that I got the position! The remaining few weeks of my internship were joyful, knowing that I would continue as an employee.

 

So, what is your role in Biomapas?

Currently, I am an assistant in the QPPV team, which operates in a wide range of various analytical tasks related to drug safety on a global scale. The acronym QPPV stands for a specific legally obliged person who is personally responsible for the pharmacovigilance process of a particular drug. The team I am part of is full of highly skilled and experienced QPPVs who have become my career mentors and advisors. It also means that this is the right team to be in if I want to become a QPPV myself one day.

 

Any wishes to the future participants?

If you keep considering what career path might be the best for you, I advise you not to doubt and apply to the Biomapas Academy. You will at least gain a broad understanding of how the drug development process works, and it’s a great addition to your resume. If you are lucky, this might become a much greater experience than just an interesting set of lectures and assignments – it could potentially lead your future career too, just like it happened to me.

From the moment I entered Biomapas, it has exceeded my expectations so far. Besides the ability to analyze medical information, I like that many other qualities are helpful in the job: from my natural proactivity to language skills. Even the sales background gained in several part-time jobs during studies reflects the versatile, client-oriented atmosphere here at work. So Biomapas is a place where all – my life science education, experience, personality, and skills – found a home, and Biomapas Academy was the project which led to finding that home.

We can never be sure of where life will bring us. And this is a fun, risk-free way to try the industry out and see if it’s the right fit for you.

Biomapas Academy

What is Clinical Research? Regulatory Affairs? Pharmacovigilance?

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

What You Need to Know about Running a Clinical Trial in Russia?

What You Need to Know about Running a Clinical Trial in Russia?

Russia is a very perspective country for international clinical trial conduction. The first international clinical trial was set up in Russia about 20 years ago only, and from than country kept a great potential for market development. In 2018 health authorities (HAs) approved 653 clinical trials (CT) in Russian Federation, less in overall numbers compared to the same indicator from 2016 – 898 approved CTs. However, this decrease was observed across all types of clinical trials except for international multicentre clinical trials (IMCT).

read more
The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The CIS Region: Excellent Potential for Patient Recruitment but is there any Risk to Quality?

The number of clinical trials worldwide is increasing more than 10% each year due to the new diseases, further research for better health products and development of new drugs. Though, for a successful clinical trial, there is a major challenge – patient recruitment, which is essential and the most challenging factor due to the increasing number of new clinical trials. In order to achieve the required patient recruitment, sponsors are looking for different solutions.

read more
Running a clinical trial in the Baltic states

Running a clinical trial in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information